Peptides for women
Peptides for women in midlife - what people use them for, where evidence is limited, and how a clinician evaluates whether an option may be appropriate.
Start here
More in Peptides for women
- Sermorelin for Women After Menopause: Evidence and SafetySermorelin after menopause should be treated as a growth hormone-axis evidence question, not as an established menopause treatment. Geref, a sermorelin acetate product, had FDA-approved history for pediatric growth-hormone deficiency and diagnostic use, but it was discontinued in 2008 and is not the same as a current compounded anti-aging product. [2] [3] In the most relevant older-adult growth hormone-releasing hormone analog study, 19 adults aged 55 to 71 had growth hormone/insulin-like growth factor 1 activation and increased skin thickness after 16 weeks, but weight and sleep did not improve, and lean-mass, insulin-sensitivity, well-being, and libido signals favored men rather than women. [1]
- CJC-1295 and Ipamorelin After Menopause: Do They Work?CJC-1295 and ipamorelin should not be treated as established menopause therapies. CJC-1295 increased growth hormone 2- to 10-fold for at least 6 days and insulin-like growth factor 1 1.5- to 3-fold for 9 to 11 days in healthy adults, but that was biomarker evidence, not a trial of women after menopause. Ipamorelin human data also show growth-hormone stimulation, while a 117-patient postoperative-ileus trial did not show significant efficacy differences on key outcomes. FDA safety materials also flag CJC-1295 and ipamorelin-related compounding concerns. [1]
- BPC-157 After Menopause: Evidence, FDA Status, and SafetyBPC-157 is not a menopause treatment with established benefits for women after menopause. A 2025 musculoskeletal review found only three human pilot reports: intra-articular knee pain, interstitial cystitis, and a 2-person intravenous safety/pharmacokinetic study. [1] FDA also lists BPC-157 among compounded bulk substances with safety uncertainties, including immunogenicity, peptide-impurity, and active-ingredient characterization concerns. [6] The July 23, 2026 FDA advisory-committee review is about possible 503A compounding-list status, not FDA approval of BPC-157 as a finished drug; FDA briefing materials propose that BPC-157 free base and BPC-157 acetate not be included on that list. [7] [8]
Common questions
Is sermorelin FDA-approved for menopause or anti-aging?
No. FDA records show Geref, a sermorelin acetate product, was approved in 1997 for pediatric growth-hormone deficiency history and related diagnostic use, then discontinued in 2008. That history does not approve compounded sermorelin for menopause, weight loss, energy, or anti-aging.
Are peptides safe for women after menopause?
Safety depends on the exact peptide, dose, route, source, and health history. FDA materials flag multiple compounded peptide substances, while approved labels have specific warnings. A safe review should name the product and include at least 1 clear monitoring plan.
What did CJC-1295 human studies show?
In healthy adults aged 21 to 61, one CJC-1295 injection increased mean growth hormone 2- to 10-fold for at least 6 days and insulin-like growth factor 1 1.5- to 3-fold for 9 to 11 days. That is biomarker evidence, not menopause outcome evidence.
Is BPC-157 established for menopause symptoms?
No. Current BPC-157 evidence does not establish benefit for hot flashes, weight, libido, skin aging, joint pain, gut symptoms, or recovery after menopause. A 2025 review found only 3 human pilot reports.